CLAIM CARD
Quantitative findings across these studies present a mixed profile, with no consistent cardiometabolic benefit or harm linked specifically to ACE inhibitors in aging contexts. Din 2026 reported a mixture of significant (P < 0.05, P < 0.05) and non-significant (P > 0.05) findings across different functional and cardiometabolic endpoints. The clinical RCT by Zhang 2025 demonstrated that both nifedipine-GITS and ramipril similarly reduced blood pressure, reporting a P = 0.02 for a comparative endpoint. By contrast, Azizzadeh 2026 reported no p-values in the provided excerpts, indicating a null or unreported effect for ACE inhibitor use on vascular aging determinants.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025